trilaciclib
E1549322
UNEXPLORED
Trilaciclib is an intravenous cyclin-dependent kinase 4/6 inhibitor used to protect bone marrow from chemotherapy-induced damage in patients with certain cancers.
All labels observed (2)
| Label | Occurrences |
|---|---|
| trilaciclib canonical | 2 |
| ribociclib | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T22690316 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: trilaciclib Context triple: [CDK4, inhibitedByDrug, trilaciclib]
-
A.
paclitaxel
Paclitaxel is a chemotherapy drug that stabilizes microtubules to inhibit cell division and is widely used to treat various cancers, including breast, ovarian, and lung cancers.
-
B.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
C.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
-
D.
Abraxane
Abraxane is a nanoparticle albumin-bound formulation of the chemotherapy drug paclitaxel used to treat various cancers, including breast, lung, and pancreatic cancer.
-
E.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: trilaciclib Target entity description: Trilaciclib is an intravenous cyclin-dependent kinase 4/6 inhibitor used to protect bone marrow from chemotherapy-induced damage in patients with certain cancers.
-
A.
paclitaxel
Paclitaxel is a chemotherapy drug that stabilizes microtubules to inhibit cell division and is widely used to treat various cancers, including breast, ovarian, and lung cancers.
-
B.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
C.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
-
D.
Abraxane
Abraxane is a nanoparticle albumin-bound formulation of the chemotherapy drug paclitaxel used to treat various cancers, including breast, lung, and pancreatic cancer.
-
E.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
- F. None of above. chosen
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: trilaciclib